Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
نویسندگان
چکیده
منابع مشابه
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology over the past 7 years has revolutionised the treatment of exudative age-related macular degeneration (AMD) and holds great promise for diabetic macular oedema, branch and central retinal vein occlusions, and retinopathy of prematurity. Each of the three available drugs (pegaptanib, bevacizumab and ran...
متن کاملIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
OBJECTIVE Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab. DESIGN Double-masked, ...
متن کاملVEGF-Trap: a VEGF blocker with potent antitumor effects.
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. Initial attempts to block VEGF by using a humanized monoclonal antibody are beginning to show promise in human cancer patients, underscoring the importance of optimizing VEGF blockade. Previous studi...
متن کاملAflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
PURPOSE Aflibercept is a soluble decoy VEGF receptor and angiogenesis inhibitor with potent preclinical antitumor activity in melanoma. We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemotherapy. EXPERIMENTAL DESIGN A two-stage design was adopted to evaluate 4-month progression-free survival rate (PFSR) and response rate. Afliberce...
متن کاملTurning a blind eye to anti-VEGF toxicities.
Excessive blood vessel growth is a key feature of many retinal diseases, and recently, anti-VEGF therapy has been successfully applied to treat neovascular age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. In this issue of the JCI, Kurihara et al. reveal an essential role of Vegfa in maintaining choroid vasculature and cone photoreceptors, critical for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Ophthalmology
سال: 2012
ISSN: 0007-1161,1468-2079
DOI: 10.1136/bjophthalmol-2011-300654